Skip to main content

Featured

FIFA World Cup 2026 & Your Wallet: How to Cash In Right Now

  The biggest sporting event in history is happening right now in Canada. Here's what it means for your money — whether you own property, rent, or just want to watch. The 2026 FIFA World Cup kicked off on Canadian soil on June 12 — and whether you've been following the matches or not, this tournament is already leaving a mark on Canadian wallets. Toronto and Vancouver are hosting games through July 19, and the economic ripple effects are very real: in hotels, short-term rentals, restaurants, and yes, your tax return. If you're a homeowner — especially in Toronto or the GTA — there's still time to benefit. And if you're simply a Canadian taxpayer, it's worth knowing exactly what this tournament is costing us, and what we're getting back. Here's everything you need to know about the FIFA World Cup and your money. The Big Picture: What This Tournament Is Worth to Canada FIFA projects that hosting the World Cup will contribute up to CAD $3.8 billion in eco...
Post a Comment
Read more

article

Labels

New Hope for Alzheimer’s Patients: Health Canada Approves First Disease-Modifying Treatment


Health Canada has granted conditional approval for LEQEMBI® (lecanemab), a groundbreaking therapy shown to slow the progression of early Alzheimer’s disease. Developed by Eisai Co., Ltd. and Biogen Inc., the drug is the first in Canada to directly target one of the underlying causes of the disease by reducing amyloid-beta aggregates in the brain.

LEQEMBI is authorized for adults diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s disease, specifically for patients who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology.

The approval follows results from the global Clarity AD Phase 3 trial, which demonstrated that lecanemab significantly slowed cognitive and functional decline compared to placebo. This milestone offers new hope to the more than 771,000 Canadians currently living with dementia, a number projected to rise to 1 million by 2030.

While the approval comes with conditions requiring further data, experts say this marks a pivotal step in shifting Alzheimer’s treatment from symptom management to disease modification.


Labels:

Comments

Post a Comment